Tarsus Pharmaceuticals, Inc.
TARS
Rang in Aktien
#4559
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Aktienkurs
$70.50
Zuletzt synchronisiert: 2026-10-21
Marktkapitalisierung
$3.30B
Veränderung (1 Tag)
-0.75%
Veränderung (1 Jahr)
2.62%
Land
US
Handel Tarsus Pharmaceuticals, Inc. (TARS)
Kategorie
Healthcare
Kursverlauf für Tarsus Pharmaceuticals, Inc. (TARS)
Höchster Schlusskurs: $72.19 am 2026-10-01
Niedrigster Schlusskurs: $21.51 am 2020-10-01
Niedrigster Schlusskurs: $21.51 am 2020-10-01
Kursverlauf der Aktie von Tarsus Pharmaceuticals, Inc. von 2020 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | -13.75% |
| 2025 | 54.26% |
| 2024 | 182.67% |
| 2023 | 21.69% |
| 2022 | -38.83% |
| 2021 | -32.39% |
| 2020 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $525.12 | 23.14% |
US
|
|
| $237.61 | 784.95% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $887.75 | 9.04% |
NL
|
|
| $289.96 | 1.88% |
BE
|
